Navigation Links
LDL particle measurement by NMR recognized by ADA, ACC

Raleigh, NC, March 28, 2008 - The American Diabetes Association (ADA) and the American College of Cardiology (ACC) issued a consensus statement today that states the measurement of LDL particle number by nuclear magnetic resonance (NMR) is one of the more accurate ways to evaluate cardiometabolic risk (CMR). The study, published in the April issue of Diabetes Care, reinforces that LDL cholesterol may not be the best way to quantify a patients risk for cardiovascular disease (CVD).

Cardiometabolic Risk (CMR) is associated with Type 2 Diabetes and CVD obesity, insulin resistance, hyperglycemia and hypertension are risk factors that often cluster together. ApoB and LDL particle concentration appear to be more closely associated with these markers of CMR than LDL cholesterol or non-HDL cholesterol. Subsequently, lipoprotein abnormalities are commonly found in patients with CMR. According to the consensus statement, ApoB and LDL particle number by NMR appear to be more discriminating measures of the adequacy of LDL lowering therapies than are traditional LDL and HDL cholesterol measures.

"Several studies have shown that LDL cholesterol (LDL-C) poorly characterizes lipid abnormalities in patients with cardiometabolic risk," says Robert S. Rosenson, MD, Director of Lipoprotein Disorders and Clinical Atherosclerosis Research, University of Michigan School of Medicine and presenter at the consensus panel meeting. "Additionally, LDL-P concentrations, compared to LDL-C and non HDL-C, have been shown to be stronger predictors of cardiovascular risk."

The NMR LipoProfile test, developed by LipoScience, Inc., is the only test that quantifies LDL particle number (LDL-P) using Nuclear Magnetic Resonance. LDL particle information is used by clinicians to monitor the effect of lipid altering interventions, such as statins, in the management of a patients cardiovascular health by lowering LDL particle number (LDL-P).

Studies show that low concentrations of LDL particles are associated with fewer cardiovascular disease related events than equivalently low levels of LDL cholesterol; data most recently published from the Framingham Offspring study in December 2007.1

This consensus statement further demonstrates the critical role that the NMR LipoProfile test can play for the millions of people with diabetes or cardiovascular disease risk, says Rick Brajer, Chief Executive Officer and President, LipoScience, Inc. Measuring LDL particle number by NMR presents physicians and patients with the opportunity to better manage cardiometabolic risk.


Contact: Maura Siefring
Dorland Global Public Relations

Related biology news :

1. Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
2. Carnegie Mellon scientist uses mass spectrometer to weigh virus particle, von Willebrand factor
3. New nanoparticle vaccine is more effective but less expensive
4. Nanoparticle exposures happen, says expert
5. Worldwide atmospheric measurements will determine the role of atmospheric fine particles
6. MIT: Remote-control nanoparticles deliver drugs directly into tumors
7. MIT sculpts 3-D particles with light
8. Technique controls nanoparticle size, makes large numbers
9. Tiny dust particles from Asian deserts common over western United States
10. Particle accelerator may reveal shape of alternate dimensions
11. Mesothelin engineered on virus-like particles provides treatment clues for pancreatic cancer
Post Your Comments:
(Date:11/12/2015)... , Nov. 11, 2015   Growing ... reliable analytical tools has been paving the way ... qualitative determination of discrete analytes in clinical, agricultural, ... are being predominantly used in medical applications, however, ... environmental sectors due to continuous emphasis on improving ...
(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... be speaking at the following conference, and invited investors ... York, NY      Tuesday, December 1, 2015 at ... York, NY      Tuesday, December 1, 2015 at ... Healthcare Conference, New York, NY ...
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  Clintrax Global, Inc., a ... North Carolina , today announced that the company has set ... represented a 391% quarter on quarter growth posted for Q3 of ... and Mexico , with the establishment ... in December 2015. --> United Kingdom ...
Breaking Biology Technology: